BioSpace News Archive

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, announced that company’s Chief Executive Officer, Frederic Ors will participate at the Vaccines Panel of the 20th Annual Biotech in Europe Forum held on September 21-24, 2020.

Century Therapeutics , developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the appointment of Michael C. Diem, MD, as Chief Business Officer. Dr. Diem has more than 15 years of experience in the global pharmaceutical and biotech industries and nearly 10 years of experience in academic and clinical medicine. “I am excited to welcome Mike to Century as he shar

Confirmed overall response rate (ORR) of 21% in the dose-escalation stage across all doses, confirmed ORR 33% at the highest and selected Phase 2 dose Target tumor shrinkage was observed in 37% of patients Preliminary data show activity in patients with melanoma, Merkel cell carcinoma (MCC), and cutaneous squamous cell carcinoma (CSCC) Phase 2 arms in both MCC and CSCC are currently recruiting CHICAGO & CAMBRIDGE,

HBM Healthcare Investments joins lead investor Sofinnova Partners and New Enterprise Associates in consortium

Alligator Bioscience announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,774,150 which covers compositions of matter directed to Alligator’s bispecific drug candidate ATOR-1015.

Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women’s health, announced that Dr Cristina Csimma has been appointed as Chair of the Board of Directors.

Domestic Feline Companion Animals May Serve as Reservoir for SARS-CoV-2 Infections in Humans

Ryvu Therapeutics announced that the first patient has been treated in Europe for the cohort expansion part of Phase II DIAMOND-01 clinical trial investigating SEL24/MEN1703, a first-in-class, oral dual PIM/FLT3 inhibitor, as single agent in Acute Myeloid Leukemia.

Knopp Biosciences LLC announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with moderate-to-severe eosinophilic asthma.

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Nick Harvey as Chief Financial Officer.